IL231757A - Antagonists ras for the treatment of malignant and non-malignant diseases - Google Patents
Antagonists ras for the treatment of malignant and non-malignant diseasesInfo
- Publication number
- IL231757A IL231757A IL231757A IL23175714A IL231757A IL 231757 A IL231757 A IL 231757A IL 231757 A IL231757 A IL 231757A IL 23175714 A IL23175714 A IL 23175714A IL 231757 A IL231757 A IL 231757A
- Authority
- IL
- Israel
- Prior art keywords
- malignant
- disease treatment
- ras antagonists
- ras
- antagonists
- Prior art date
Links
- 230000003211 malignant effect Effects 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544471P | 2011-10-07 | 2011-10-07 | |
| PCT/US2012/058900 WO2013052765A1 (en) | 2011-10-07 | 2012-10-05 | Malignant and non-malignant disease treatment with ras antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL231757A0 IL231757A0 (en) | 2014-05-28 |
| IL231757A true IL231757A (en) | 2017-07-31 |
Family
ID=48044179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL231757A IL231757A (en) | 2011-10-07 | 2014-03-27 | Antagonists ras for the treatment of malignant and non-malignant diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9309203B2 (https=) |
| EP (1) | EP2763681B1 (https=) |
| JP (1) | JP6165744B2 (https=) |
| CN (1) | CN103906518B (https=) |
| AU (1) | AU2012318471B9 (https=) |
| CA (1) | CA2849421C (https=) |
| ES (1) | ES2642843T3 (https=) |
| IL (1) | IL231757A (https=) |
| MX (1) | MX364551B (https=) |
| RU (1) | RU2632097C2 (https=) |
| WO (1) | WO2013052765A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9738614B2 (en) | 2011-10-07 | 2017-08-22 | Pisces Therapeutics, Llc | Malignant and non-malignant disease treatment with Ras antagonists |
| CN103304499B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 抗糖尿病化合物、其制备方法和用途 |
| CN103304500B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 新型抗糖尿病化合物、其制备方法和用途 |
| CN103304501B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一类抗糖尿病化合物、其制备方法和用途 |
| CN103304498B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一种抗糖尿病化合物、其制备方法和用途 |
| CN103304503B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 抗糖尿病化合物、其制备方法和用途 |
| KR20160091920A (ko) | 2013-11-18 | 2016-08-03 | 예일 유니버시티 | 트랜스포존 조성물 및 이의 이용 방법 |
| WO2016056606A1 (ja) * | 2014-10-07 | 2016-04-14 | 国立大学法人京都大学 | ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品 |
| JP6875745B2 (ja) * | 2016-02-16 | 2021-05-26 | 国立大学法人大阪大学 | 線維化を治療するための医薬組成物 |
| TR201920922A2 (tr) * | 2019-12-20 | 2020-06-22 | Ankara Ueniversitesi | 3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107587A (en) | 1993-11-12 | 1998-08-16 | Univ Ramot | Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation |
| AU4723897A (en) * | 1996-10-24 | 1998-05-15 | Kyowa Hakko Kogyo Co. Ltd. | 1,4-benzoquinone derivatives |
| JP2001513890A (ja) | 1997-02-26 | 2001-09-04 | サイレオス コーポレーション | リポタンパク質の膜アンカーを標的とする薬剤スクリーニング法 |
| GEP20043214B (en) * | 1999-01-21 | 2004-04-26 | Bristol Myers Squibb Company Us | Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same |
| US20050119237A1 (en) | 1999-06-18 | 2005-06-02 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Non-malignant disease treatment with Ras antagonists |
| JP2003502365A (ja) * | 1999-06-18 | 2003-01-21 | サイリオス・コーポレイション | Ｒａｓアンタゴニストによる非悪性疾患処置 |
| US20020115696A1 (en) * | 1999-06-18 | 2002-08-22 | Yoel Kloog | Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists |
| US20070054886A1 (en) | 2003-05-23 | 2007-03-08 | Ramot At Tel Aviv University, Ltd. | Ras antagonists for treating neurodegenerative disorders |
| ES2414861T3 (es) * | 2004-08-18 | 2013-07-23 | Kadmon Corporation, Llc | Uso del FTS para el tratamiento de trastornos malignos |
| WO2007064448A2 (en) | 2005-11-28 | 2007-06-07 | Ramot At Tel Aviv University, Ltd. | Cancer treatment using fts and 2-deoxyglucose |
| EP1986625B1 (en) | 2006-02-10 | 2012-08-01 | Ramot at Tel-Aviv University Ltd. | Treatment of ovarian cancer |
| CA2648518C (en) | 2006-04-11 | 2012-06-26 | Ramot At Tel Aviv University Ltd. | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor |
| WO2007144889A2 (en) | 2006-06-14 | 2007-12-21 | Ramot At Tel Aviv University Ltd. | Treatment of neurofibromatosis |
| WO2008075342A1 (en) | 2006-12-19 | 2008-06-26 | Ramot At Tel Aviv University Ltd. | Treatment of lung cancer |
| WO2009048541A2 (en) * | 2007-10-05 | 2009-04-16 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
-
2012
- 2012-10-05 CA CA2849421A patent/CA2849421C/en not_active Expired - Fee Related
- 2012-10-05 JP JP2014534755A patent/JP6165744B2/ja not_active Expired - Fee Related
- 2012-10-05 RU RU2014118430A patent/RU2632097C2/ru active
- 2012-10-05 WO PCT/US2012/058900 patent/WO2013052765A1/en not_active Ceased
- 2012-10-05 ES ES12838578.8T patent/ES2642843T3/es active Active
- 2012-10-05 AU AU2012318471A patent/AU2012318471B9/en not_active Ceased
- 2012-10-05 MX MX2014004126A patent/MX364551B/es active IP Right Grant
- 2012-10-05 US US14/350,303 patent/US9309203B2/en not_active Expired - Fee Related
- 2012-10-05 CN CN201280048941.1A patent/CN103906518B/zh not_active Expired - Fee Related
- 2012-10-05 EP EP12838578.8A patent/EP2763681B1/en not_active Not-in-force
-
2014
- 2014-03-27 IL IL231757A patent/IL231757A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014118430A (ru) | 2015-11-20 |
| JP6165744B2 (ja) | 2017-07-19 |
| IL231757A0 (en) | 2014-05-28 |
| US20140249163A1 (en) | 2014-09-04 |
| CA2849421A1 (en) | 2013-04-11 |
| MX364551B (es) | 2019-04-30 |
| EP2763681B1 (en) | 2017-08-16 |
| EP2763681A4 (en) | 2015-04-15 |
| AU2012318471B2 (en) | 2017-05-04 |
| JP2014528453A (ja) | 2014-10-27 |
| AU2012318471A1 (en) | 2014-05-22 |
| EP2763681A1 (en) | 2014-08-13 |
| AU2012318471B9 (en) | 2017-06-01 |
| MX2014004126A (es) | 2014-07-28 |
| ES2642843T3 (es) | 2017-11-20 |
| CA2849421C (en) | 2020-04-28 |
| WO2013052765A1 (en) | 2013-04-11 |
| US9309203B2 (en) | 2016-04-12 |
| CN103906518A (zh) | 2014-07-02 |
| RU2632097C2 (ru) | 2017-10-02 |
| CN103906518B (zh) | 2020-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267242B (en) | Cancer treatment | |
| GB2495841B (en) | Phytocannabinoids for use in the treatment of breast cancer | |
| IL231757A (en) | Antagonists ras for the treatment of malignant and non-malignant diseases | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| SG11201501653RA (en) | Methods for the treatment of locally advanced breast cancer | |
| EP2675469A4 (en) | COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | |
| IL239007B (en) | Eribulin for use in the treatment of breast cancer | |
| EP2751267A4 (en) | METHOD FOR THE TREATMENT OF BREAST CANCER | |
| LT2901341T (lt) | Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui | |
| LT2819663T (lt) | Nauji terapiniai parkinsono ligos gydymo būdai | |
| ZA201306613B (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| PT2872176T (pt) | Carboranilporpirinas para utilização no tratamento de cancro | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| EP2564852A4 (en) | ACTIVE AGAINST BRAIN TUMORS | |
| GB201222563D0 (en) | Cancer treatment | |
| PL2797898T3 (pl) | Pochodne piperazynylowe do leczenia nowotworów | |
| GB201116328D0 (en) | Treatment for tumours | |
| GB201204645D0 (en) | Treatment of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |